RESUMEN
BACKGROUND: The majority of women with breast cancer experience treatment-related fatigue. Fatigue makes patients more inclined to terminate their treatment, which influences patient prognosis and survivorship. PURPOSE: This study explores the effects of a walking program on fatigue and exercise capacity in women who have undergone breast cancer surgery. METHODS: This was a randomized control trial study with measures taken 3 times over 5 weeks. Sixty-six women with breast cancer were recruited from a medical center in central Taiwan. The intervention was a moderate-intensity, home-based walking program. The Functional Assessment for Chronic Illness Treatment-Fatigue and distance walked in a 6-minute period, respectively, were used to score the main outcome measures of fatigue and exercise capacity. RESULTS: For those who accepted chemotherapy, fatigue was significantly higher during chemotherapy than after surgery. Although participants in the walking program achieved gradually reduced fatigue and increased exercise capacity, there was no significant difference in fatigue and exercise capacity between the exercise and control groups at any of the three measured times. CONCLUSIONS/IMPLICATIONS FOR PRACTICE: Nurse collaboration with healthcare providers to promote exercise in the breast cancer population may not only improve the health of post-surgery breast cancer women but also enhance the independent functioning of nurses and advance the nursing profession.
Asunto(s)
Neoplasias de la Mama/fisiopatología , Ejercicio Físico , Fatiga/etiología , Caminata , Adulto , Neoplasias de la Mama/cirugía , Femenino , Humanos , Persona de Mediana EdadRESUMEN
PURPOSE: Fucoidan is a dietary supplement which is commonly used by cancer patients. However, despite evidence of positive effects in cell culture environments, there are currently no clinical guidelines for supplementary use of fucoidan in cancer patients. This study aims to evaluate the effectiveness of fucoidan supplemental use. METHODS: A systematic literature search was conducted using databases including Cochrane Library, JBI, PubMed, Embase, and CINAHL. All original studies on fucoidan for supplemental use in cancer patients were included. The search was made in databases without time restriction. The outcomes included disease progression status, inflammatory markers, nutritional status, adverse effects, and quality of life. The appraisal tool used was JBI-MAStARI. RESULTS: Four studies were included: One randomized controlled trial and three quasi-experimental studies. Meta-analysis was not applied due to the heterogeneity of measurement tools. Overall sample size was 118. Most participants were metastatic colorectal and gastric cancer patients. Two studies revealed a significantly longer survival time and chemotherapy treatment periods with fucoidan use. Positive but insignificant effects of disease control rate, inflammatory markers, nutrition status, fatigue, and financial difficulty were shown in those using fucoidan. CONCLUSIONS: The results of this systematic review indicate that the effects of fucoidan were inconsistent with clinical outcomes in metastatic or recurrent cancer patients. Only four studies were included, and heterogeneity in methodologies and relatively small sample sizes limited the research consensus. Although cause and effect between fucoidan and the survival time, disease control or adverse effects could not be confirmed, this study includes the most research on fucoidan in humans.